Philip B. Mcglave
#162,155
Most Influential Person Now
Philip B. Mcglave's AcademicInfluence.com Rankings
Philip B. Mcglavephilosophy Degrees
Philosophy
#9387
World Rank
#12940
Historical Rank
Logic
#6366
World Rank
#7878
Historical Rank
Philip B. Mcglavebiology Degrees
Biology
#12909
World Rank
#16415
Historical Rank
Immunology
#870
World Rank
#893
Historical Rank
Download Badge
Philosophy Biology
Philip B. Mcglave's Degrees
- PhD Immunology University of California, San Francisco
- Doctorate Medicine Stanford University
Why Is Philip B. Mcglave Influential?
(Suggest an Edit or Addition)Philip B. Mcglave's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. (2005) (1560)
- Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. (2011) (1002)
- Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. (2005) (891)
- Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. (1988) (875)
- Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. (1996) (649)
- Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. (2007) (498)
- Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. (2007) (461)
- Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. (1990) (362)
- Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. (1987) (334)
- Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. (2014) (325)
- Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. (2016) (312)
- Varying intensity of postremission therapy in acute myeloid leukemia. (1992) (299)
- Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma (1990) (292)
- Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. (2009) (284)
- Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. (1992) (283)
- Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. (1986) (274)
- RISK FACTORS FOR ACUTE GRAFT‐VERSUS‐HOST DISEASE IN HISTOCOMPATIBLE DONOR BONE MARROW TRANSPLANTATION (1991) (269)
- Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. (1987) (260)
- A randomized study of the prevention of acute graft-versus-host disease. (1982) (238)
- Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. (2000) (234)
- Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor. (1994) (229)
- B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome (1999) (220)
- Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. (1992) (219)
- Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. (2005) (218)
- Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin (1991) (217)
- Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. (2002) (203)
- Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. (1995) (186)
- Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups (1994) (185)
- Respiratory Syncytial Virus‐Induced Acute Lung Injury in Adult Patients with Bone Marrow Transplants: A Clinical Approach and Review of the Literature (1989) (183)
- Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. (1988) (181)
- The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture. (1992) (179)
- Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. (1994) (171)
- Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. (2006) (168)
- Adhesion of committed human hematopoietic progenitors to synthetic peptides from the C-terminal heparin-binding domain of fibronectin: cooperation between the integrin alpha 4 beta 1 and the CD44 adhesion receptor. (1994) (167)
- Depressed mood and other variables related to bone marrow transplantation survival in acute leukemia. (1991) (167)
- Extrinsic risk factors for pneumonia in the patient at high risk of infection. (1984) (166)
- A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. (1985) (165)
- Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. (1993) (162)
- Studies on the liver to kidney switch of erythropoietin production. (1981) (162)
- Hepatic Graft Versus Host Disease: A Study of the Predictive Value of Liver Biopsy in Diagnosis (1984) (159)
- Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement. (1985) (158)
- Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. (1990) (156)
- Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. (1988) (156)
- Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. (2004) (151)
- Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. (2001) (142)
- PRETREATMENT OF DONOR BONE MARROW WITH MONOCLONAL ANTIBODY OKT3 FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HISTOCOMPATIBLE BONE-MARROW TRANSPLANTATION (1982) (142)
- A Prospective Study of Infectious Diseases Following Bone Marrow Transplantation: Emergence of Aspergillus and Cytomegalovirus as the Major Causes of Mortality (1983) (133)
- Role of monocytes in the expansion of human activated natural killer cells. (1992) (133)
- A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. (2000) (128)
- Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. (1993) (127)
- Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. (1998) (118)
- Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. (1990) (116)
- Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program (1993) (111)
- Recommended Guidelines for the Management of Autologous and Allogeneic Bone Marrow Transplantation: A Report from the Eastern Cooperative Oncology Group (ECOG) (1994) (106)
- Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease. (1987) (105)
- Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. (1992) (105)
- HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. (2009) (103)
- Hemotherapy in patients undergoing blood group incompatible bone marrow transplantation (1983) (101)
- Unrelated donor bone marrow transplantation for children with acute leukemia. (1997) (100)
- In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts [see comments] (1989) (99)
- Intensive therapy followed by bone marrow transplantation for patients with acute lymphocytic leukemia in second or subsequent remission: determination of prognostic factors (a report from the University of Minnesota Bone Marrow Transplantation Team). (1983) (98)
- Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. (1988) (97)
- Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units (2009) (96)
- Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. (1997) (95)
- Nodular regenerative hyperplasia of the liver following bone marrow transplantation (1989) (94)
- Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. (2008) (93)
- Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. (2009) (92)
- Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation. (2013) (91)
- Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. (1992) (89)
- Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. (1996) (84)
- Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. (1994) (84)
- Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation (2005) (82)
- Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. (2010) (81)
- Leukemia inhibitory factor/human interleukin for DA cells: a growth factor that stimulates the in vitro development of multipotential human hematopoietic progenitors. (1991) (81)
- Invasive Fusarium infections in bone marrow transplant recipients. (1984) (79)
- Unrelated Donor Bone Marrow Transplantation for Chronic Myelogenous Leukemia: A Decision Analysis (1997) (76)
- Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow. (1987) (76)
- Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. (1995) (75)
- Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia: a pilot study. (1982) (74)
- BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. (1996) (74)
- Response to thalidomide therapy in refractory chronic graft-versus-host disease (2000) (73)
- Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. (1994) (68)
- SUCCESSFUL ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS IN THE ACCELERATED PHASE OF CHRONIC GRANULOCYTIC LEUKAEMIA (1982) (68)
- Factors Predicting Single-Unit Predominance after Double Umbilical Cord Blood Transplantation (2011) (67)
- Unrelated donor bone marrow transplantation therapy for chronic myelogenous leukemia. (1987) (65)
- Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation. (1987) (65)
- Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. (2001) (64)
- Treatment of marrow stroma with interferon-alpha restores normal beta 1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1 alpha. (1995) (64)
- Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. (1990) (63)
- Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. (1996) (61)
- A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections. (2003) (59)
- Comparison of two total body irradiation regimens in allogeneic bone marrow transplantation for acute non-lymphoblastic leukemia in first remission. (1990) (58)
- In vitro suppression of erythropoiesis by bone marrow adherent cells from some patients with fungal infection (1982) (58)
- Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. (1994) (58)
- Total lymphoid irradiation and cyclophosphamide conditioning prior to bone marrow transplantation for patients with severe aplastic anemia. (1983) (57)
- Comparison of engraftment in recipients of matched sibling of unrelated donor marrow allografts. (1994) (56)
- Bone marrow transplantation for acute nonlymphocytic leukemia in first remission: analysis of prognostic factors. (1985) (56)
- Autologous transplantation therapy for chronic myelogenous leukemia. (1997) (55)
- Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors. (1987) (54)
- Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation (1987) (53)
- Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival. (1995) (53)
- Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. (1990) (51)
- Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival. (1990) (50)
- Diagnostic open-lung biopsy after bone marrow transplantation. (1990) (50)
- Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity. (1989) (49)
- Frequent HLA class I and DP sequence mismatches in serologically (HLA-A, HLA-B, HLA-DR) and molecularly (HLA-DRB1, HLA-DQA1, HLA-DQB1) HLA-identical unrelated bone marrow transplant pairs. (1994) (49)
- Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective. (1996) (46)
- Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. (1994) (46)
- Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation. (2016) (46)
- Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. (1995) (45)
- Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF. (1997) (44)
- Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. (2000) (44)
- Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. (2009) (44)
- Bone marrow transplantation for non-Hodgkin's lymphoma in children and young adults. A pilot study. (1983) (43)
- A clinically suitable ex vivo expansion culture system for LTC-IC and CFC using stroma-conditioned medium. (1997) (43)
- High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation (2010) (41)
- T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease. (1990) (39)
- Natural killer cell proliferation is dependent on human serum and markedly increased utilizing an enriched supplemented basal medium. (1995) (36)
- Extramedullary presentation of the blast crisis of chronic myelogenous leukaemia (1985) (36)
- Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. (1996) (35)
- In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. (1989) (35)
- A critical comparison of allogeneic bone marrow transplantation and conventional chemotherapy as treatment for acute nonlymphocytic leukemia. (1984) (35)
- Reduced Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor. (2007) (34)
- Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. (1988) (33)
- Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. (2011) (33)
- Chronic myelogenous leukemia (1995) (33)
- Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma. (1995) (32)
- Allogeneic bone marrow transplantation for acute leukaemia: comparative outcomes for adults and children (1988) (31)
- Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation (2000) (30)
- Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma (2007) (30)
- Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience. (1996) (28)
- Highly Variable Mycophenolate Mofetil Bioavailability Following Nonmyeloablative Hematopoietic Cell Transplantation (2007) (28)
- Frequent HLA class I and DP sequence mismatches in serologically (HLA-A, HLA-B, HLA-DR) and molecularly (HLA-DRB1, HLA-DQA1, HLA-DQB1) HLA-identical unrelated bone marrow transplant pairs. (1994) (27)
- Unrelated donor bone marrow transplantation for hematological malignancies-current status. (1996) (27)
- Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support. (1990) (25)
- Treatment of chronic myelogenous leukemia with bone marrow transplantation. (1990) (24)
- Efficacy of high‐dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma (2006) (24)
- Graft‐versus‐host disease prophylaxis with anti‐T‐cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone‐marrow transplantation (1985) (23)
- Bone marrow transplants using volunteer donors--recommendations and requirements for a standardized practice throughout the world. The Executive Committee of the World Marrow Donor Association. (1992) (23)
- BCR/ABL- CD34+HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal (1999) (22)
- Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors. (1991) (22)
- Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. (2005) (22)
- Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation. (1993) (22)
- Allogeneic bone marrow transplantation as treatment for accelerating chronic myelogenous leukemia (1984) (22)
- Determinants of survival after human leucocyte antigen‐matched unrelated donor bone marrow transplantation in adults (2002) (20)
- Allogeneic bone marrow transplantation with related donors other than HLA MLC-matched siblings, and the use of antithymocyte globulin, prednisone, and methotrexate for prophylaxis of graft-versus-host disease. (1985) (19)
- Bone marrow transplantation versus chemotherapy in acute non-lymphocytic leukemia: a meta-analytic review. (1989) (18)
- Cytogenetic conversion following allogeneic bone marrow transplantation for advanced chronic myelogenous leukemia. (1981) (17)
- Cytogenetic conversion following allogeneic bone marrow transplantation for advanced chronic myelogenous leukemia (1981) (17)
- Successful allogeneic cryopreserved marrow transplantation (1989) (17)
- An expanded role for cord blood transplantation. (1991) (17)
- Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation. (1987) (16)
- Autologous bone marrow versus non‐mobilized peripheral blood stem cell transplantation for lymphoid malignancies: A prospective, comparative trial (1997) (15)
- Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. (2004) (14)
- Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma (2005) (14)
- Successful Haploidentical Hematopoietic Cell Engraftment Using a Non-Myeloablative Preparative Regimen Including Natural Killer (NK) Cells (2008) (14)
- Population dynamics of human activated natural killer cells in culture (1994) (13)
- Therapy of chronic myelogenous leukemia with related or unrelated donor bone marrow transplantation. (1992) (12)
- Comparative Analysis of Autografting in Chronic Myelogenous Leukemia: Effects of Priming Regimen and Marrow or Blood Origin of Stem Cells (1998) (12)
- The biology and treatment of chronic myelogenous leukemia. (2001) (12)
- BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal. (1999) (11)
- Autologous hematopoietic cell transplantation for chronic myelogenous leukemia. (2004) (10)
- Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. (2019) (9)
- Allogeneic bone marrow transplantation as treatment for accelerating chronic myelogenous leukemia. (1984) (9)
- Effectiveness of a regional bone marrow donor program. (1988) (9)
- Therapy of chronic myelogenous leukemia with bone marrow transplantation. (1990) (9)
- Unrelated donor and autologous marrow transplant therapy of chronic myelogenous leukemia (CML). (1993) (9)
- T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors. (1995) (9)
- Comprar Hematology, 5th Ed. Basic Principles and Practice (Expert Consult Premium Edition - Enhanced Online Features and Print) | Philip McGlave | 9780443067136 | Churchill Livingstone (2009) (9)
- Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells. (1998) (9)
- Empirical antibacterial therapy in febrile, granulocytopenic bone marrow transplant patients (1984) (8)
- Bone marrow transplantation for chronic myelogenous leukemia. (1998) (8)
- A Novel Triple Umbilical Cord Blood Transplant (UCBT) Strategy To Promote NK Cell Immunotherapy (Unit 1) with a Fully Ablative Preparative Regimen Followed by a Double UCBT in Patients with Refractory AML. (2006) (8)
- Kinetics of Chimerism and Unit Predominance After Double Umbilical Cord Blood Transplantation (2010) (8)
- Interaction of primitive human myeloid and lymphoid progenitors with the marrow microenvironment. (1994) (8)
- Expansion and activation of human natural killer cells for autologous therapy. (1994) (7)
- Bone marrow transplantation. New strategies for treating malignant disease. (1996) (7)
- Unrelated donor transplant therapy for chronic myelogenous leukemia. (1998) (7)
- Bone Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic Phase (2020) (6)
- Autologous bone marrow versus non-mobilized peripheral blood stem cell transplantation for lymphoid malignancies: a prospective, comparative trial. (1997) (6)
- Cyclophosphamide & total body irradiation versus busulfan & cyclophosphamide: A randomized comparison of 2 conditioning regimens in autologous bone marrow transplantation for acute myeloid leukemia (1994) (6)
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Acute Lymphocytic Leukemia (ALL) in 126 Adults: Impact of Donor Source on Leukemia Free Survival (LFS). (2005) (6)
- Treatment of donor bone marrow with OKT3 (PAN-T monoclonal antibody) for prophylaxis of graft-vs.-host disease (GvHD) in histocompatible allogeneic bone marrow transplantation (BMT): a pilot study. (1982) (6)
- Recombinant granulocyte/macrophage-colony stimulating factor in human and murine bone marrow transplantation. (1988) (6)
- Chronic myelogenous leukemia: In search of the benign hematopoietic stem cell (1993) (6)
- HLA class I and II antigen phenotypes of North American Indians from Minnesota: implications for marrow transplants using unrelated donors (1990) (6)
- Allogeneic and Autologous Marrow Transplantation: Ex vivo Purging with Monoclonal Antibody or Immunotoxins to Remove Leukemic Cells or to Prevent Graft Versus Host Disease (1986) (5)
- Chronic myelogenous leukemia. (1996) (5)
- Cyclophosphamide/GM-CSF priming in autotransplant therapy for CML. (1996) (5)
- Favorable Leukemia-Free Survival (LFS) for Adults and Children Undergoing Myeloablative Umbilical Cord Blood (UCB) Transplantation with Cyclophosphamide (CY), Fludarabine (FLU) and Total Body Irradiation (TBI): A Single Center Analysis of 194 Patients (2009) (5)
- Hematology, 5th Ed. Basic Principles and Practice (Expert Consult Premium Edition - Enhanced Online Features and Print) (2009) (5)
- Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy (1997) (5)
- Expansion and activation of human natural killer cells as therapy for autologous transplantation. (1994) (4)
- Erythropoietin and hemoglobin switching. (1980) (4)
- Donor and host influences in bone marrow transplantation for immunodeficiency disease and leukemia. (1993) (4)
- Intravenous immunoglobulin for treatment of necrobiotic xanthogranuloma (2018) (4)
- Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group. (1990) (3)
- with umbilical cord blood: safety profile and detection kinetics Infusion of ex vivo expanded T regulatory cells in adults transplanted (2011) (3)
- Hematopoietic Stem-Cell Transplantation from an Unrelated Donor (2000) (3)
- Fludarabine Pharmacokinetics in Nonmyeloablative Hematopoietic Cell Transplantation (HCT): Association with Engraftment and Neurotoxicty. (2005) (3)
- The results of allogeneic bone marrow transplantation (BMT) in patients with acute non-lymphocytic leukemia (ANLL) in first remission: Comparison of two sequential studies utilizing different total body irradiation regimens (1987) (3)
- Creation of a double chimera by transplantation of two unrelated donor umbilical cord blood units (2000) (3)
- Treatment of CML with unrelated donor marrow transplant. (1993) (3)
- Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report (2019) (3)
- Chronic myelogenous leukemia (1999) (2)
- Autologous stem cell transplantation for the treatment of chronic myelogenous leukemia. (1997) (2)
- Favorable Leukemia-Free Survival (LFS) for Adults and Children Undergoing Myeloablative Umbilical Cord Blood (UCB) Transplantation with Cyclophosphamide (CY), Fludarabine (FLU) and Total Body Irradiation (TBI): A Single Center Analysis of 194 Patients. (2008) (2)
- BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA (1985) (2)
- Successful Remission of Poor Prognosis AML after Adoptive Transfer and In Vivo Expansion of Human Haploidentical NK Cells. (2004) (2)
- Diminished ALAK Cytotoxicity and Proliferation Accompany Disease Progression in Chronic Myelogenous Leukemia (2003) (2)
- 229: Umbilical cord blood transplantation for adult patients with chronic myeloid leukemia (2007) (2)
- Prognostic factors in patients undergoing bone marrow transplantation for acute nonlymphocytic leukemia (1985) (2)
- Autografting for chronic myelocytic leukemia. (1994) (2)
- enhance engraftment in adults with hematologic malignancy Transplantation of two partially HLA-matched umbilical cord blood units to (2009) (2)
- Optimal NK Cell Expansion Depends on Accessory Cells, Synergy between Physiologic Concentrations of IL-2 and IL-15, and Umbilical Cord Blood (UCB) NK Cell Precursors Expand Better Than Adult NK Cells. (2006) (2)
- Allele Level HLA Matching On Outcomes After Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies: Stronger Graft Vs. Leukemia with HLA Mismatch (2012) (1)
- Correlation of HLA-DP disparity, primary MLC reactivity, and incidence of graft versus host disease (GVHD) in unrelated bone marrow transplant recipients (1991) (1)
- The status of bone marrow transplantation for leukemia. (1985) (1)
- Autologous Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia (2007) (1)
- 29: A Novel Triple Umbilical Cord Blood Transplant (UCBT) Strategy to Promote NK Cell Immunotherapy (Unit 1) with a Fully Ablative Preparative Regimen Followed By a Double UCBT in Patients with Refractory AML (2007) (1)
- Analysis of 595 marrow transplants for the treatment of chronic myeloid leukemia from unrelated donors facilitated by the US national marrow donor program (NMDP): Effect of HLA class II allele disparity on clinical outcome (1996) (1)
- [Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia]. (1995) (1)
- Bone marrow transplantation at the University of Minnesota. (1982) (1)
- Current Therapy of Chronic Myelogenous Leukemia (1998) (1)
- Fludarabine Exposure Is Associated with Increased Treatment Related Mortality after Nonmyeloablative Hematopoietic Cell Transplantation (HCT) (2008) (1)
- Allogeneic transplantation for chronic myelogenous leukemia (2005) (1)
- NK cell killing of AML and ALL blasts by Killer-Immunoglobulin Receptor (KIR) negative NK cells after NKG2A and LIR-1 blockade Marrow (2010) (1)
- transplantation comparative analysis of unrelated versus matched sibling donor Allogeneic bone marrow transplantation for chronic myelogenous leukemia (2013) (1)
- CYTOMEGALOVIRUS PNEUMONIA AFTER BONE MARROW TRANSPLANTATION (1993) (1)
- CHRONIC LEUKEMIAS. AUTHOR'S REPLY (1998) (0)
- Long-Term Morbidity and Mortality Experienced By Chronic Myeloid Leukemia (CML) Patients after Allogeneic Hematopoietic Cell Transplantation (HCT) - a Report from BMTSS-2 (2016) (0)
- remission: analysis of prognostic factors Bone marrow transplantation for acute nonlymphocytic leukemia in first (2011) (0)
- The Predictive Value of the Hematopoietic Cell Transplantation (HCT)-Specific Comorbidity Index (CI) in Recipients of Umbilical Cord Blood (UCB) Transplantation. (2007) (0)
- Effects of Priming Regimen and Marrow or Blood Origin of Stem Cells Comparative Analysis of Autografting in Chronic Myelogenous Leukemia (2010) (0)
- Killer Immunoglobulin Receptor (KIR) Negative NK Cells Exhibit Potent Alloreactivity Against Primary Leukemia Targets When Interrupting MHC Class I Interactions through NKG2A Blockade. (2007) (0)
- Autologous versus allogeneic stem cell transplant for multiple myeloma (2004) (0)
- 10: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Acute Lymphocytic Leukemia (ALL) in 126 Adults: Impact of Donor Source on Leukemia Free Survival (LFS) (2006) (0)
- Factors predicting favorable outcome following autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s disease: A prognostic model based on 20 year follow up (2005) (0)
- cells is improved using IL-2 diphtheria toxin fusion protein Clearance of acute myeloid leukemia by haploidentical natural killer (2014) (0)
- Bone marrow transplantation for non-Hodgkin's lymphoma in children and young adults. A pilot study (1983) (0)
- NK Cell KIR Reconstitution after Allogeneic Hematopoietic Cell Transplant (HCT) Is Affected by T Cell Number and Function. (2005) (0)
- IL-2 Stimulated Treg Inhibit in Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo, (2011) (0)
- Abnormal marrow microenvironmental function in chronic myelogenous leukemia is related to the presence of malignant stromal macrophages (1994) (0)
- Multiple class I and DP sequence mismatches in most serologically- and Dw-identical unrelated donor/recipient marrow pairs (1992) (0)
- Transient regulatory T-cell (Treg) depletion with IL-2 diphtheria toxin fusion protein enhances clearance of acute myeloid leukemia by haploidentical natural killer (NK) cells (2013) (0)
- Autologous Bone Marrow Transplantation for Patients With Acute Lymphoblastic Leukemia in Second or Subsequent Remission : Results of Bone Marrow Treated With Monoclonal Antibodies BAi BAi BAi , BA2 BA2 BA2 , and BA3 BA3 BA3 Plus Complement By (2005) (0)
- Bone marrow transplantation for chronic myelogenous leukemia: clinical outcomes. (1994) (0)
- Comprar Hematology: Basic Principles and Practice, Expert Consult Premium Edition - Enhanced Online Features and Print, 6e | Philip McGlave | 9781437729283 | Churchill Livingstone (2013) (0)
- Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies. (1992) (0)
- Encouraging Results of Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation for the Treatment of Advanced Lymphoid Malignancies. (2007) (0)
- Optimizing selection of unrelated donors for successful bone marrow transplantation (1988) (0)
- The international prognostic index at relapse predicts autologous stem cell transplantation outcome for aggressive non-Hodgkin's lymphoma in second remission or chemosensitive first relapse (2004) (0)
- Predictive factors for adequate hematopoietic stem cell mobilization with hematopoietic growth factor alone in patients with lymphoma (2005) (0)
- Weight loss, skin rash, and cough following bone marrow transplantation for chronic myelogenous leukemia. (1998) (0)
- Bone marrow transplantation for severe aplastic anemia following preparation with cyclophosphamide and total lymphoid irradiation. (1984) (0)
- CD44 adhesion receptor fibronectin: cooperation between the integrin alpha 4 beta 1 and the synthetic peptides from the C-terminal heparin-binding domain of Adhesion of committed human hematopoietic progenitors to (2010) (0)
- Blocking Inhibitory KIR Is Insufficient for Optimal Killing of AML and ALL Targets: Additional Requirements for NKG2A and LIR-1 Blockade (2008) (0)
- Study of hemoglobin switching in sheep: is switching regulated by environmental influences? (1983) (0)
- Impact of Graft Source on Immune Recovery: Comparions Between Unrelated Umbilical Cord Blood (UCB), HLA Matched Sibling (Sib) Donor and Autologous (Auto) Hematopoietic Stem Cells. (2010) (0)
- ALLOGENEIC BONE MARROW TRANSPLANTATION WITH RELATED DONORS OTHER THAN HLA MLC‐MATCHED SIBLINGS, AND THE USE OF ANTITHYMOCYTE GLOBULIN, PREDNISONE, AND METHOTREXATE FOR PROPHYSAXIS OF GRAFT‐VERSUS‐HOST DISEASE (1985) (0)
- In Memoriam: A Tribute to Esmail Zanjani, 1938–2019 (2019) (0)
- myelogenous leukemia progenitors in long-term culture Autologous activated natural killer cells suppress primitive chronic (2002) (0)
- High Resolution HLA Matched Unrelated Donor Versus HLA Identical Sibling Transplantation for Chronic Phase CML. (2007) (0)
- RANDOMIZED COMPARISON OF CYCLOPHOSPHAMIDE-TOTAL (1995) (0)
- The international prognostic index at relapse predicts autologous stem cell transplantation outcome for aggressive non-Hodgkin's lymphoma in second remission or chemosensitive first relapse. (2004) (0)
- graft-versus-leukemia effect in recipients of 2 units Relapse risk after umbilical cord blood transplantation: enhanced (2013) (0)
- Total lymphoid irradiation (TLI) and cyclophosphamide (CPM) as preconditioning for bone marrow transplantation (BMT) in severe aplastic anemia (AA) (1980) (0)
- Long term follow up after autologous hematopoietic stem cell transplantation for low grade non-Hodgkin's lymphoma. (2004) (0)
- 51 Conditioning regimens TN autologous bone marrow transplantation for acute myeloid leukemia: Patient age and remission status influence choice of optimum conditioning regimen (1995) (0)
- myelogenous leukemia on the basis of HLA-DR antigen expression Selection of benign primitive hematopoietic progenitors in chronic (2003) (0)
- Oral Bioavailability of Mycophenolate Mofetil in Patients Undergoing Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Is Poor and Highly Variable. (2005) (0)
This paper list is powered by the following services:
